FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | colorectal cancer | Regulators | ImClone | Erbitux

SPOTLIGHT: Emclone seeks expanded Erbitux approval

Tools

Imclone has filed for regulatory approval for a new use for Erbitux. Approved in early 2004 for colorectal cancer, Imclone is asking the FDA to approve expanded use for squamous-cell carcinoma of the head and neck. Story


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about ImClone   Erbitux   FDA   colorectal cancer   Regulators